# Efficacy and Safety of Roflumilast Cream 0.3% in Subjects With Plaque Psoriasis: a Phase 3 Study

> **NCT06648772** · PHASE3 · RECRUITING · sponsor: **Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.** · enrollment: 189 (estimated)

## Conditions studied

- Plaque Psoriasis

## Interventions

- **DRUG:** Roflumilast Cream 0.3%
- **DRUG:** Vehicle cream

## Key facts

- **NCT ID:** NCT06648772
- **Lead sponsor:** Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-14
- **Primary completion:** 2025-06-28
- **Final completion:** 2025-07-04
- **Target enrollment:** 189 (ESTIMATED)
- **Last updated:** 2025-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06648772

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06648772, "Efficacy and Safety of Roflumilast Cream 0.3% in Subjects With Plaque Psoriasis: a Phase 3 Study". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06648772. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*